SCHEMBL4711312

SCHEMBL4711312

Clc1ccc(C(c2ccc(Cl)cc2)c2cccc(N3CCC3)c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 11/20 0.49
▸ CYP1A2 P05177 2/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ CYP2D6 P10635 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ MAPT P10636 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ HIF1A Q16665 1/20 0.43
▸ HTR3E A5X5Y0 1/20 0.42
▸ HTR3B O95264 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ ADRB1 P08588 1/20 0.42
▸ HTR1A P08908 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ HTR2A P28223 1/20 0.42
▸ HTR2C P28335 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30407444 0.75 HTR3E (0.69) CYP1A2CYP3A4CYP2D6CYP2C19MAPT
SCHEMBL26770369 0.75 HTR3E (0.69) CYP1A2CYP3A4CYP2D6CYP2C19MAPT
SCHEMBL14349225 0.74 NOTUM (0.54) MEN1KMT2ATSHRADRB1LMNA
SCHEMBL11644110 0.73 ALDH1A1 (0.57) CNR1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL7763010 0.72 ALDH1A1 (0.50) CNR1CYP3A4CYP2D6TSHRHIF1A
SCHEMBL29595602 0.71 HTR3E (0.69) CYP1A2CYP3A4CYP2D6CYP2C19MEN1
SCHEMBL1822683 0.71 HTR3E (0.69) CYP1A2CYP3A4CYP2D6CYP2C19MEN1
SCHEMBL3534359 0.70 NOTUM (0.54) MEN1KMT2AMAPTTSHRADRB1
SCHEMBL24103508 0.70 SIGMAR1 (0.64) MEN1KMT2AMAPTALOX15HTR3E
SCHEMBL11922752 0.70 HTR3E (0.67) CYP1A2CYP3A4CYP2D6CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1962834-A2 USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA Aventis Pharmaceuticals Inc. (US) 2008-09-03 — — EP claimed
WO-2007067617-A2 USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA AVENTIS PHARMACEUTICALS INC. (US) 2007-06-14 — — WO claimed
EP-1962834-A2 USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA Aventis Pharmaceuticals Inc. (US) 2008-09-03 — — EP disclosed
WO-2007067617-A2 USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA AVENTIS PHARMACEUTICALS INC. (US) 2007-06-14 — — WO disclosed
Send feedback